Neurogene Inc. Deferred Tax Assets, Operating Loss Carryforwards, Foreign
Neurogene Inc. (NGNE) had Deferred Tax Assets, Operating Loss Carryforwards, Foreign of $0 as of 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign · last filed 2021-03-25
- 2020-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $0.00.
- 2019-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $39.57M.
- 2018-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $40.25M.
- 2017-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $35.60M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Foreign | Deferred Tax Assets, Operating Loss Carryforwards, Foreign as first filed |
|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-25 | |
| 2019-12-31 | $39.57M 10-K · filed 2021-03-25 | |
| 2018-12-31 | $40.25M 10-K · filed 2020-03-12 | |
| 2017-12-31 | $35.60M 10-K · filed 2019-03-07 | |
| 2016-12-31 | $24.05M 10-K · filed 2018-03-12 | |
| 2015-12-31 | $18.28M 10-K · filed 2017-03-09 | |
| 2014-12-31 | $13.86M 10-K · filed 2016-03-14 | $13.86M 10-K · filed 2015-03-16 |
| 2013-12-31 | $10.56M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |